Summary: In the present study, the eŠects on expression of cytochrome P450 (CYP1A1, CYP1A2, CYP3A4 and CYP3A5), carboxylesterase (CES1 and CES2) and sulfotransferase (CHST1, CHST3, CHST4, CST, SULT2A1 and TPST2) mRNA in primary cultures of cryopreserved human hepatocytes were evaluated after exposure to NO-1886 (diethyl 4-[(4-bromo-2-cyanophenyl) carbamoyl] benzylphosphonate) for 48 hr at 2, 10, and 50 mM. Analysis was performed by RT-PCR in the presence of TaqMan probe. CYP1A1 and CYP1A2 mRNA levels after exposure to 50 mM omeprazole (positive control for CYP1As) were increased by 162 ( pº0.001) and 37 times ( pº0.001), respectively, compared with untreated controls. However, these mRNA levels were increased by 2 times or less after exposure to NO-1886. CYP3A4 and CYP3A5 mRNA levels after exposure to 50 mM rifampicin (positive control for CYP3As) were signiˆcantly increased by 5.8 ( pº0.01) and 2.0 times ( pº0.01), respectively, compared with untreated controls. The CYP3A4 mRNA level after exposure to 10 mM NO-1886 was increased by 1.3 times ( pº0.05). Further, the CYP3A4 mRNA level after exposure to 50 mM NO-1886 was signiˆcantly increased by 3.6 times ( pº0.001). However, the CYP3A5 mRNA level after exposure to 50 mM NO-1886 was not signiˆcantly increased. CES1 and CES2 mRNA levels after exposure to 50 mM NO-1886 were signiˆcantly increased by 1.4 ( pº0.05) and 2.6 times ( pº0.01), respectively, compared with untreated controls. CHST1, CST and SULT2A1 mRNA levels after exposure to 50 mM NO-1886 were signiˆcantly increased by 3.8 ( pº0.001), 1.8 ( pº0.01) and 4.4 times ( pº0.01), respectively. CHST3, CHST4 and TPST2 mRNA levels after exposure to 50 mM NO-1886 were not signiˆcantly increased. This in vitro technique using primary cultured human hepatocytes is expected to be very useful for the preclinical evaluation of the induction of drug-metabolizing enzymes in humans.
Introduction
There is a growing body of evidence showing an association between triglycerides and an increased risk of coronary heart disease. 1) Hypertriglyceridemia, which by itself is an independent risk factor, is particularly common in certain speciˆc groups of individuals, such as people with high plasma levels of low-density lipoprotein (LDL) cholesterol.
2) Many studies have reported that exercise decreases plasma total cholesterol and triglyceride levels and increases HDL cholesterol levels. 3, 4) Furthermore, it has been shown that exercise improves insulin resistance in patients with diabetes mellitus. 5) These results indicate that exercise provides protection against the development of atherosclerosis. It has been reported that the novel compound NO-1886 (ibrolipim) ( Fig. 1) is an eŠective lipoprotein lipase activator and that long-term administration of NO-1886 also protects against the development of experimental atherosclerosis in animals. 6) The pharmacokinetics and metabolic pathways ( Fig. 1 ) of NO-1886 were investigated in previous studies by Morioka et al., [7] [8] [9] who reported that NO-1886 is metabolized by cytochrome P450, carboxylesterase and sulfotransferase. The in vivo metabolic pathways of NO-1886 in the rat and cynomolgus monkey have been identiˆed as the O-deethylation of phosphonate and the hydrolysis of the amide bond. 7, 9) The main metabolite is monoethyl phosphonate (M-2), which has been reported to account for 70z and 94z of all metabolites in the rat 7) and cynomolgus monkey, 9) respectively. It has been demonstrated that the O-deethylation of phosphonate is performed by liver P450 enzymes and that the amino bond is hydrolyzed by liver microsomal carboxylesterase (CES). 8) In addition, rat plasma CES (CES1C isozyme) is mainly responsible for amide hydrolysis in the rat. 9) Since plasma CES1C is absent in humans and monkeys, the amide hydrolysis of NO-1886 is reduced in the cynomolgus monkey in vivo. 9) In contrast, human liver microsomes exhibited only O-deethylation of NO-1886. 8) Both CYP3A4 and CYP2C8 are major P450 enzymes involved in the phosphonate O-deethylation of NO-1886 in the human liver.
8) The level of amide hydrolysis was 5z that of O-deethylation in the human liver homogenate 9000 g supernatant. 8 ) Therefore, human CES contributes only slightly to the amide hydrolysis of NO-1886 in comparison with the rat and cynomolgus monkey. Furthermore, O-deethylation by P450 enzymes showed almost nô rst-pass metabolism of NO-1886 in the liver, and NO-1886 was eliminated from the body slowly.
8)
Drug-drug interactions are an important consideration in drug development. Human hepatocytes are used for the evaluation of gene induction of drug-metabolizing enzymes after exposure to drugs. 10, 11) We previously reported a method for evaluating the gene induction of drug-metabolizing enzymes after exposure to model drugs such as rifampicin and omeprazole 12) in primary cultures of human hepatocytes. Rifampicin is a potent inducer of CYP3As in primary cultures of human hepatocytes 10) and omeprazole is a potent inducer of CYP1As in such cells. 11) In the present study, we conducted preclinical evaluations of the eŠects of NO-1886 on gene induction of drug-metabolizing enzymes such as cytochrome P450s (CYP1A1, CYP1A2, CYP3A4 and CYP3A5), carboxylesterases (CES1 and CES2) and sulfotransferases (CHST1, CHST3, CHST4, CST, SULT2A1 and TPST2), which are related to the metabolism of NO-1886, using primary cultures of cryopreserved human hepatocytes. All other chemicals and reagents used were of analytical reagent grade.
Materials and Methods

Materials
Monolayer culture of hepatocytes: The cryopreserved human hepatocytes were suspended in Hepatocyte Culture Medium. The hepatocytes were centrifuged (45g, 49 C) for 3 min and resuspended in the same medium. The number of cells was counted using a Coulter Counter. Cell suspensions with viability rates of 85z to 90z as assessed by trypan blue dye exclusion were used for the experiments. The cell suspensions were diluted to aˆnal concentration of 2.5×10 5 viable cells W mL using Hepatocyte Culture Medium, and inocula of 1×10 5 viable cells W 0.4 mL W well were introduced into 24-well plates that had been coated with type I collagen. The cells were cultured for 3 hr after inoculation under 5z CO2 and 95z air at 379 C. The medium was then replaced with fresh medium, and the cells were cultured for 21 hr under 5z CO2 and 95z air at 379 C. The medium was then replaced with fresh medium without human epidermal growth factor (hEGF), gentamicin, or amphotericin B, and the cells were cultured for 24 hr under 5z CO2 and 95z air at 379 C. The cells were used for experiments at 48 hr after inoculation.
Experiments using monolayer cultures of hepatocytes: At 48 hr after inoculation, the hepatocytes were treated with a number of known inducers for an additional 48 hr. Media with the inducers but without hEGF, gentamicin, or amphotericin B were changed daily during treatment and the cells were cultured under 5z CO2 and 95z air at 379 C. The eŠects of NO-1886 at concentrations of 2, 10 and 50 mM were studied. The eŠects of rifampicin and omeprazole at a concentration of 50 mM were also studied. All inducers were dissolved in DMSO at aˆnal vehicle concentration of 0.1z (v W v). Controls were also exposed at DMSO at aˆnal vehicle concentration of 0.1z (v W v). Total RNA was extracted from the hepatocytes using the Rneasy } Mini Kit and QIAshredder TM . Oligonucleotides: The forward and reverse primers and TaqMan probes used for quantitative analysis were the same as those employed in our previous study.
12 ) The primers and TaqMan probes were synthesized by QIAGEN (Tokyo, Japan). The TaqMan probes contained 6-carboxy‰uorescein (FAM) at the 5? end and 6-carboxytetramethylrhodamine (TAMRA) at the 3? end and were designed to hybridize to a sequence located between the PCR primers.
TaqMan RT-PCR conditions: Human total RNA was diluted with yeast tRNA to 50 mg W mL. The RT-PCR assay was performed using 50 mL of TaqMan One-Step RT-PCR Master Mix Reagents containing 300 nM forward primer, 900 nM reverse primer, 200 nM TaqMan probe and about 20 ng of total RNA. Ampliˆcation and detection were performed using the ABI PRISM 7700 Sequence Detector system (Applied Biosystems) with the following proˆle: 1 cycle of 489 C for 30 min, 1 cycle of 959 C for 10 min and 50 cycles each of 959 C for 15 sec and 609 C for 1 min. For GAPDH, 200 nM forward primer, 200 nM reverse primer and 100 nM TaqMan probe were used; for bactin, 300 nM forward primer, 300 nM reverse primer and 200 nM TaqMan probe were used.
Speciˆcity of RT-PCR between CYP3A4 and CYP3A5: A cross-reactivity assay was performed to determine whether our assay system could quantify the target molecule speciˆcally. Total RNA was extracted from Escherichia coli transfected with human CYP3A4 13) or CYP3A5 (Kamataki, T. unpublished observation). Measurements of CYP3A4 and CYP3A5 gene expression were obtained individually using CYP3A4-and CYP3A5-speciˆc primer sets and probes.
Statistical analysis: The data were analyzed using the ABI PRISM Sequence Detector System software (Sequence Detector Ver. 1.9.1). The relative expression of each mRNA was calculated by the DCt method (where DCt is the value obtained by subtracting the Ct value of b-actin mRNA from the Ct value of the target mRNA), which was employed in our previous study. 14) Speciˆcally, the amount of target mRNA relative to b-actin mRNA was expressed as 2
. Data are expressed as the ratio of the target mRNA to b-actin mRNA. Further, the values are given as results relative to controls with 0.1z DMSO. Statistical analysis was performed using the Student's t-test with a signiˆcance level of pº0.05.
Results
Quantitative analysis and speciˆcities: The forward and reverse primers and TaqMan probes used for the quantitative analysis were the same as those employed in our previous study. 12) Analysis was performed by RT-PCR using the ABI PRISM 7700 Sequence Detector System in the presence of the TaqMan probe. The RT-PCR method is widely used for the analysis of mRNA expression, and the most important issue in this method is its selectivity for the target gene. Both the primers and probes were homology searched by an NCBI BLAST search to ensure that they were speciˆc for the target mRNA transcript. Further, in order to study the selectivity for CYP3A4 and CYP3A5 mRNA, a crossreactivity assay was performed to determine whether our assay system could quantify the target molecule speciˆcally. Measurements of CYP3A4 and CYP3A5 gene expression in Escherichia coli transfected with human CYP3A4 13) and CYP3A5 (Kamataki, T. unpublished observation) were obtained individually using CYP3A4-and CYP3A5-speciˆc primer sets and probes. The ability of this method to discriminate between CYP3A4 gene expression and CYP3A5 gene expression was clearly conˆrmed, with cross contamination of less 1×10 -6 (data not shown). The ability of this method to discriminate between CYP1A1 gene expression and CYP1A2 gene expression has already been reported in the literature.
15)
EŠects of NO-1886 on mRNA expression: In the present study, the levels of gene expression of cytochrome P450s (CYP1A1, CYP1A2, CYP3A4 and CYP3A5), carboxylesterases (CES1 and CES2) and sulfotransferases (CHST1, CHST3, CHST4, CST, SULT2A1 and TPST2) were evaluated in primary cultures of cryopreserved hepatocytes after 48-hr exposure to NO-1886 (2, 10 and 50 mM) and the typical known enzyme inducers rifampicin (50 mM) and omeprazole (50 mM). All experiments were performed in the presence of 0.1z DMSO. None of the treatments showed any identiˆable toxic eŠects such as cell death or loss of adhesion of hepatocytes at the study concentrations employed, as assessed by microscopic examination. The levels of GAPDH mRNA, which were normalized to those of b-actin mRNA, showed no changes after exposure to NO-1886, omeprazole or rifampicin compared with untreated controls (data not shown). Therefore, it is considered that the expression of both GAPDH and b-actin mRNA after exposure to NO-1886, omeprazole or rifampicin did not change to the levels in untreated controls. Figure 2 shows the levels of CYP1A1 and CYP1A2 mRNA expression. The levels of CYP1A1 and CYP1A2 mRNA in human hepatocytes after exposure to omeprazole, which was the positive control for CYP1As, were increased by 162 ( pº0.001) and 37 times ( pº0.001), respectively, compared with untreated controls. However, these mRNA levels were increased by 2 times or less after exposure to NO-1886 compared with untreated controls. Figure 3 shows the levels of mRNA expression of CYP3A4 and CYP3A5. The levels of CYP3A4 and CYP3A5 mRNA after exposure to 50 mM rifampicin, which was the positive control for CYP3As, were signiˆcantly increased by 5.8 ( pº0.01) and 2.0 times ( pº0.01), respectively, compared with untreated controls. The level of CYP3A4 mRNA after exposure to 10 mM NO-1886 was increased by 1.3 times ( pº0.05) compared with untreated controls. Further, the level of CYP3A4 mRNA after exposure to 50 mM NO-1886 was signiˆcantly increased by 3.6 times ( pº0.001) compared with untreated controls. However, the level of CYP3A5 mRNA after exposure to 50 mM NO-1886 showed no change compared with untreated controls. Figure 4 shows the levels of mRNA expression of the carboxylesterases CES1 and CES2. The levels of CES1 and CES2 mRNA after exposure to 50 mM NO-1886 were signiˆcantly increased by 1.4 ( pº0.05) and 2.6 times ( pº0.01), respectively, compared with untreated controls. Figure 5 shows the levels of mRNA expression of the sulfotransferases CHST1, CHST3, CHST4, CST, SULT2A1 and TPST2. The levels of CHST1, CST and SULT2A1 mRNA after exposure to 50 mM NO-1886 were signiˆcantly increased by 3.8 ( pº0.001), 1.8 ( pº0.01) and 4.4 ( pº0.01) times, respectively, compared with untreated controls. The levels of CHST3, CHST4 and TPST2 mRNA after exposure to 50 mM NO-1886 showed no changes compared with untreated controls.
Discussion
In standard induction studies, the activity of drugmetabolizing enzymes is evaluated in liver samples after repeated administration to female rats. However, species diŠerences in the induction of drug-metabolizing enzymes are frequently observed in the metabolism of xenobiotics. Therefore, the fact that there are species diŠerences between experimental animal and human data is an important issue in pharmacological e‹cacy and toxicity studies conducted during drug development. For example, although rifampicin does not induce CYP3A1 in the rat, it is a potent inducer of CYP3A4 in humans. 16) The diŠerences observed in the results of pharmacological studies employing diŠerent species are due, at least in part, to species diŠerences in CYP3A as assessed using liver microsomes and the expression system of CYP3A.
The CYP3A subfamily is the major cytochrome P450 expressed in the human liver. 17) CYP3A is responsible for approximately 50z of the cytochrome P450-mediated metabolism of drugs 18) and is an important enzyme with respect to the side eŠects and actions of drugs and their metabolites. CYP3A4 is the most abundantly expressed CYP, accounting for approximately 30z to 40z of the total CYP content in the adult human liver.
17) It is generally accepted that CYP3A4 is the main member of the CYP3A subfamily expressed in the liver in the majority of humans, followed by CYP3A5, whereas CYP3A7 and CYP3A43 are expressed at much lower levels. 19) We have therefore focused on the induction of CYP3A4 and CYP3A5 in the human liver. A recent report characterizing the genetic basis of polymorphic CYP3A5 expression found that CYP3A5 was expressed in 60z of the livers of AfricanAmericans compared with 33z for Caucasians and that CYP3A5 represented at least 50z of the total hepatic CYP3A content in people polymorphically expressing CYP3A5. 20) CYP3A5, as well as CYP3A4, may be an important contributor to interindividual and interracial diŠerences in CYP3A-dependent drug clearance and in responses to many pharmaceutical agents. In addition, Williams et al. 18) reported an equal or reduced metabolic capability for CYP3A5 as compared with CYP3A4. Baune et al. 21) reported that both CYP3A4 and CYP3A5 metabolize halofantrine, with CYP3A4 playing a major role. Shou et al. 22) reported that CYP3A4 shows a 10-fold greater apparent a‹nity for taxotere than CYP3A5, but that both have a similar maximal velocity.
It has previously been reported that CYP3A4 is clearly induced in human hepatocytes after exposure at 2 mM or less to many drugs such as paclitaxel 10) and troglitazone. 23) In our previous study involving the primary culture of cryopreserved human hepatocytes, we also reported that CYP3A4 mRNA was clearly induced by exposure to 2 mM rifampicin. 12) Recently, the induction of CYP3A5 mRNA in the human liver has also been reported by Burk et al. 24) Therefore, we conducted detailed investigations into the mRNA expression proˆles of CYP3A4 and CYP3A5. As shown in Fig. 3 , the levels of CYP3A4 and CYP3A5 mRNA in human hepatocytes were increased after exposure to rifampicin. However, the induction rate of the mRNA expression of CYP3A5 was lower than that of CYP3A4. In addition, the levels of CYP3A4 mRNA after exposure to 10 mM and 50 mM NO-1886 showed only a slight increase of 1.3 times and a signiˆcant increase of 3.6 times, respectively, compared with untreated controls (Fig. 3) , while the level of CYP3A5 mRNA after exposure to 50 mM NO-1886 was not signiˆcantly increased. In the present study, we found that CYP3A4, which was mainly responsible for metabolizing NO-1886, 8) was induced by exposure to NO-1886, and CYP3A5, which metabolized NO-1886 only slightly, 8) was not induced by exposure to NO-1886. This in vitro technique using primary cultured human hepatocytes is expected to be very useful for evaluating diŠerences in the induction of CYP3A4 and CYP3A5 in humans.
It should also be noted that the induction of CYP3A4 by xenobiotics has profound clinical implications. For example, known P450 inducers such as carbamazepine and phenytoin enhance the clearance of co-administered drugs, thereby reducing their e‹cacy. 25) Therefore, NO-1886, which induces CYP3A4 mRNA, may enhance the clearance of co-administered drugs, thereby reducing their e‹cacy. Since the hepatic clearance of NO-1886 estimated from enzymatic parameters is much lower than the hepatic blood ‰ow rate, 8) the clearance of NO-1886 itself might be increased after induction of CYP3A4. However, Morioka et al. 9) reported that the plasma Cmax value of NO-1886 at a dose of 3 mg W mL in the cynomolgus monkey was about 1.5 mg W mL (3.3 mM) and protein binding in cynomolgus monkey plasma was 86.0z. The free plasma concentration of NO-1886 in the cynomolgus monkey was about 0.46 mM, which was too low to induce CYP3A4 in human hepatocytes. Based on the plasma concentration, it is thought that no induction of CYP3A4 should occur. However, it is considered that monitoring the changes in the blood concentration of NO-1886 during clinical studies may be important in evaluating the possibility of induction of CYP3A4.
CES has been found to be frequently involved in the detoxiˆcation process of several types of ester compounds. Morioka et al. 9) reported that the amide hydrolysis of NO-1886 to M-3 (4-[(diethoxyphosphoryl) methyl] benzoic acid) is catalyzed by CES in the rat and cynomolgus monkey but not in humans. Interestingly, in the present study, we found that CES1 and CES2 were induced in primary cultures of human hepatocytes by exposure to 50 mM NO-1886, although the levels of CES1 and CES2 mRNA after exposure to 10 mM NO-1886 were not signiˆcantly increased compared with untreated controls (Fig. 4) . The induced CES1 and CES2 might not aŠect the clearance of NO-1886 itself. On the other hand, changes in CES activity have important clinical implications, since many drugs such as meperidine 26) and heroin 27) are metabolized by CES.
Morioka et al. [7] [8] [9] have reported that NO-1886 is biotransformed to M-5 (2-amino-5-bromo-3-cyanobenzene sulphate) via M-I (2-amino-5-bromo-benzonitrile) and W or M-4 (2-amino-5-bromo-3-hydroxybenzonitrile) by sulfotransferase. There have been few reports on the induction of sulfotransferase by exposure to drugs, although it has been reported that SULT2A mRNA is induced by hydrocortisone in male rat hepatocytes 28) and that SULT2A1 mRNA and protein are induced by vitamin D in VDR-transfected HepG2 cells and Caco-2 cells. 29) In the present study, we found that the sulfotransferases CHST1, CST and SULT2A1 were induced in primary cultures of human hepatocytes by exposure to 50 mM NO-1886. However, the levels of CHST1, CST and SULT2A1 mRNA after exposure to 10 mM NO-1886 were not signiˆcantly increased compared with untreated controls (Fig. 5) . Therefore, the disposition of NO-1886 that has been biotransformed by sulfotransferases may be in‰uenced by the induction of these sulfotransferases after exposure to NO-1886.
NO-1886 serves as a substrate for enzymes such as cytochrome P450, CES and sulfotransferase. [7] [8] [9] In addition, NO-1886 induces mRNA expression of many enzymes such as CYP3A4, CES1, CES2, CHST1, CST and SULT2A1. Taken together, these results suggest that NO-1886 and W or co-administered drugs may exhibit altered pharmacokinetics under the conditions of a repeated drug administration schedule, indicating that careful optimization of drug dosing regimens is required.
In conclusion, this in vitro technique using primary cultured human hepatocytes is expected to be very useful for evaluating the induction of drug-metabolizing enzymes in humans. It is suitable for evaluation in the development of new drugs for the assessment of the in vitro induction of a large number of drug-metabolizing enzymes. Finally, we emphasize the important role of drug induction studies using human hepatocytes in the development of new drugs, since such studies avoid the problem of species diŠerences between experimental animal and human data and can be expected to improve the e‹cacy and safety of future clinical drug therapy.
